GeoVax Labs’ (GOVX) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of GeoVax Labs (NASDAQ:GOVX) in a report published on Friday,Benzinga reports. D. Boral Capital currently has a $18.00 price target on the stock.

GeoVax Labs Stock Down 12.6 %

Shares of GeoVax Labs stock opened at $1.11 on Friday. GeoVax Labs has a 12-month low of $1.09 and a 12-month high of $11.18. The company has a market capitalization of $10.47 million, a price-to-earnings ratio of -0.20 and a beta of 3.06. The firm’s 50-day moving average price is $1.67 and its two-hundred day moving average price is $2.13.

GeoVax Labs (NASDAQ:GOVX) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.49. The firm had revenue of $3.00 million for the quarter, compared to the consensus estimate of $2.38 million. On average, sell-side analysts expect that GeoVax Labs will post -4.49 earnings per share for the current year.

Hedge Funds Weigh In On GeoVax Labs

Several hedge funds and other institutional investors have recently modified their holdings of the business. Northern Trust Corp acquired a new stake in GeoVax Labs in the fourth quarter valued at about $29,000. Virtu Financial LLC bought a new position in shares of GeoVax Labs in the third quarter worth about $97,000. Citadel Advisors LLC acquired a new stake in shares of GeoVax Labs in the 4th quarter valued at approximately $104,000. Finally, Geode Capital Management LLC grew its holdings in shares of GeoVax Labs by 59.0% during the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after purchasing an additional 33,440 shares during the last quarter. Institutional investors own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.